메뉴 건너뛰기




Volumn 47, Issue 10, 2007, Pages 1311-1319

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: In vitro and clinical studies

Author keywords

Cinacalcet; CYP2D6; Dextromethorphan; Drug interaction; Pharmacokinetics

Indexed keywords

3 METHOXYMORPHINAN; CALCIMIMETIC AGENT; CINACALCET; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; DEXTRORPHAN; DRUG METABOLITE; NORLEVORPHANOL; PLACEBO; QUINIDINE; UNCLASSIFIED DRUG;

EID: 34648828029     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007304103     Document Type: Article
Times cited : (59)

References (40)
  • 1
    • 0032584086 scopus 로고    scopus 로고
    • Calcimimetics with potent and selective activity on parathyroid calcium receptor
    • Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998 ; 95: 4040-4045.
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 4040-4045
    • Nemeth, E.F.1    Steffey, M.E.2    Hammerland, L.G.3
  • 2
    • 0036904133 scopus 로고    scopus 로고
    • Calcimimetics: Therapeutic potential in hyperparathyroidism. Curr Opi
    • Cohen A., Silverberg SJ Calcimimetics: therapeutic potential in hyperparathyroidism. Curr Opi Pharmacol. 2002 ; 2: 734-739.
    • (2002) Pharmacol. , vol.2 , pp. 734-739
    • Cohen, A.1    Silverberg, S.J.2
  • 3
    • 0021326821 scopus 로고
    • Parathyroid hormone and bone histology: Response to hypocalcemia in osteitis fibrosa
    • Voigts A., Felsenfeld AJ, Andress D., et al. Parathyroid hormone and bone histology: response to hypocalcemia in osteitis fibrosa. Kidney Int. 1987 ; 25: 445-452.
    • (1987) Kidney Int. , vol.25 , pp. 445-452
    • Voigts, A.1    Felsenfeld, A.J.2    Andress, D.3
  • 4
    • 0028788558 scopus 로고
    • Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patient without aluminum toxicity
    • Wang M., Herez G., Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patient without aluminum toxicity. Am J Kidney Dis. 1995 ; 26: 836-844.
    • (1995) Am J Kidney Dis. , vol.26 , pp. 836-844
    • Wang, M.1    Herez, G.2    Sherrard, D.J.3
  • 5
    • 0031920748 scopus 로고    scopus 로고
    • Association of serum phosphorous and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study
    • Block GA, Hulbert-Sharon TE, Levin NW, et al. Association of serum phosphorous and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998 ; 31: 607-617.
    • (1998) Am J Kidney Dis. , vol.31 , pp. 607-617
    • Block, G.A.1    Hulbert-Sharon, T.E.2    Levin, N.W.3
  • 6
    • 0033920728 scopus 로고    scopus 로고
    • Increased risk of hip fracture among patients with end-stage renal disease
    • Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000 ; 58: 396-399.
    • (2000) Kidney Int. , vol.58 , pp. 396-399
    • Alem, A.M.1    Sherrard, D.J.2    Gillen, D.L.3
  • 7
    • 0034084251 scopus 로고    scopus 로고
    • Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
    • Block GA, Port FK Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000 ; 35: 1226-1237.
    • (2000) Am J Kidney Dis. , vol.35 , pp. 1226-1237
    • Block, G.A.1    Port, F.K.2
  • 8
    • 0034682247 scopus 로고    scopus 로고
    • Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
    • Goodman WG, Goldin J., Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000 ; 342: 1478-1483.
    • (2000) N Engl J Med. , vol.342 , pp. 1478-1483
    • Goodman, W.G.1    Goldin, J.2    Kuizon, B.D.3
  • 9
    • 0037373070 scopus 로고    scopus 로고
    • The calcimimetic AMG073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease
    • Quarles LC, Sherrard DJ, Adler S., et al. The calcimimetic AMG073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003 ; 14: 575-583.
    • (2003) J Am Soc Nephrol. , vol.14 , pp. 575-583
    • Quarles, L.C.1    Sherrard, D.J.2    Adler, S.3
  • 10
    • 6444245707 scopus 로고    scopus 로고
    • The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism
    • Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 ; 63: 248-254.
    • (2003) Kidney Int. , vol.63 , pp. 248-254
    • Lindberg, J.S.1    Moe, S.M.2    Goodman, W.G.3
  • 11
    • 11144353767 scopus 로고    scopus 로고
    • Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
    • Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004 ; 350: 1516-1525.
    • (2004) N Engl J Med. , vol.350 , pp. 1516-1525
    • Block, G.A.1    Martin, K.J.2    De Francisco, A.L.3
  • 12
    • 2942511328 scopus 로고    scopus 로고
    • The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis
    • Ohashi N., Uematsu T., Nagashima S., et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol. 2004 ; 576: 726-734.
    • (2004) Br J Clin Pharmacol. , vol.576 , pp. 726-734
    • Ohashi, N.1    Uematsu, T.2    Nagashima, S.3
  • 13
    • 33846405177 scopus 로고    scopus 로고
    • In vitro metabolism and prediction of drug-drug interactions of calcimimetic agent cinacalcet HCl
    • Bajpai M., Esmay J., Chi V., Hayashi M., Poppe L., Kumar G. In vitro metabolism and prediction of drug-drug interactions of calcimimetic agent cinacalcet HCl. Drug Metab Rev. 2005 ; 37: 124.
    • (2005) Drug Metab Rev. , vol.37 , pp. 124
    • Bajpai, M.1    Esmay, J.2    Chi, V.3    Hayashi, M.4    Poppe, L.5    Kumar, G.6
  • 14
    • 0031723235 scopus 로고    scopus 로고
    • Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
    • Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev. 1998 ; 50: 387-411.
    • (1998) Pharmacol Rev. , vol.50 , pp. 387-411
    • Ito, K.1    Iwatsubo, T.2    Kanamitsu, S.3    Ueda, K.4    Suzuki, H.5    Sugiyama, Y.6
  • 15
    • 1942455361 scopus 로고    scopus 로고
    • Database analyses for the prediction of in vivo drug-drug interactions from in vitro data
    • [erratum in Br J Clin Pharmacol. 58: 565-568 ].
    • Ito K., Brown HS, Houston JB Database analyses for the prediction of in vivo drug-drug interactions from in vitro data [erratum in Br J Clin Pharmacol. 58: 565-568 ]. Br J Clin Pharmacol. 2004 ; 57: 473-486.
    • (2004) Br J Clin Pharmacol. , vol.57 , pp. 473-486
    • Ito, K.1    Brown, H.S.2    Houston, J.B.3
  • 16
    • 28844476587 scopus 로고    scopus 로고
    • In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: Qualitative relationships, quantitative predictions, and the rank-order approach
    • Obach RS, Walsky RL, Venkatakrishnan K., Houston JB, Tremaine LM In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharamacol Ther. 2005 ; 78: 582-592.
    • (2005) Clin Pharamacol Ther. , vol.78 , pp. 582-592
    • Obach, R.S.1    Walsky, R.L.2    Venkatakrishnan, K.3    Houston, J.B.4    Tremaine, L.M.5
  • 18
    • 0031971273 scopus 로고    scopus 로고
    • Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan
    • Basci NE, Bozkurt A., Kayaalp SO, Sayal A., Isimer A. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan. Eur J Drug Metab Pharmacokinet. 1998 ; 23: 1-5.
    • (1998) Eur J Drug Metab Pharmacokinet , vol.23 , pp. 1-5
    • Basci, N.E.1    Bozkurt, A.2    Kayaalp, S.O.3    Sayal, A.4    Isimer, A.5
  • 19
    • 0022338958 scopus 로고
    • Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
    • Schmid B., Bircher J., Preisig R., Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Phamacol Ther. 1985 ; 38: 618-624.
    • (1985) Clin Phamacol Ther , vol.38 , pp. 618-624
    • Schmid, B.1    Bircher, J.2    Preisig, R.3    Küpfer, A.4
  • 20
    • 18844369894 scopus 로고    scopus 로고
    • Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm
    • Ito K., Hallifax D., Obach RS, Houston JB Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos. 2005 ; 33: 837-844.
    • (2005) Drug Metab Dispos. , vol.33 , pp. 837-844
    • Ito, K.1    Hallifax, D.2    Obach, R.S.3    Houston, J.B.4
  • 21
    • 0033994866 scopus 로고    scopus 로고
    • Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver
    • Kanamitsu S., Ito K., Sugiyama Y. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res. 2000 ; 17: 336-343.
    • (2000) Pharm Res. , vol.17 , pp. 336-343
    • Kanamitsu, S.1    Ito, K.2    Sugiyama, Y.3
  • 22
    • 0027167470 scopus 로고
    • Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
    • Brøsen K., Hansen JG, Nielsen KK, Sindrup SH, Gram LF Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993 ; 44: 349-355.
    • (1993) Eur J Clin Pharmacol. , vol.44 , pp. 349-355
    • Brøsen, K.1    Hansen, J.G.2    Nielsen, K.K.3    Sh, S.4    Gram, L.F.5
  • 23
    • 0032847231 scopus 로고    scopus 로고
    • Influence of CYP2D6 activity on the disposition and cardiovascular toxicity and the antidepressant agent venlafaxine in humans
    • Lessard É., Yessine MA, Hamelin BA, O'Hara G., LeBlanc J., Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity and the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999 ; 9: 435-443.
    • (1999) Pharmacogenetics. , vol.9 , pp. 435-443
    • Lessard, É.1    Ma, Y.2    Hamelin, B.A.3    O'Hara, G.4    Leblanc, J.5    Turgeon, J.6
  • 24
    • 0029853347 scopus 로고    scopus 로고
    • The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans
    • Capon DA, Bochner F., Kerry N., Mikus G., Danz C., Somogyi AA The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996 ; 60: 295-307.
    • (1996) Clin Pharmacol Ther. , vol.60 , pp. 295-307
    • Capon, D.A.1    Bochner, F.2    Kerry, N.3    Mikus, G.4    Danz, C.5    Somogyi, A.A.6
  • 26
    • 9344234385 scopus 로고    scopus 로고
    • Pharmacokincetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily
    • Harris RZ, Padhi D., Marbury TC, Noveck RJ, Salfi M., Sullivan JT Pharmacokincetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis. 2004 ; 44: 1070-1076.
    • (2004) Am J Kidney Dis. , vol.44 , pp. 1070-1076
    • Harris, R.Z.1    Padhi, D.2    Marbury, T.C.3    Noveck, R.J.4    Salfi, M.5    Sullivan, J.T.6
  • 27
    • 19544367799 scopus 로고    scopus 로고
    • No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar®/Mimpara®)
    • Padhi D., Harris RZ, Salfi M., Sullivan J. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar®/Mimpara®). Clin Pharmacokinet. 2005 ; 44: 509-516.
    • (2005) Clin Pharmacokinet. , vol.44 , pp. 509-516
    • Padhi, D.1    Harris, R.Z.2    Salfi, M.3    Sullivan, J.4
  • 29
    • 0034770465 scopus 로고    scopus 로고
    • Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models
    • Venkatakrishnan K., von Moltke LL, Greenblatt DJ Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol. 2001 ; 41: 425-432.
    • (2001) J Clin Pharmacol. , vol.41 , pp. 425-432
    • Venkatakrishnan, K.1    Von Moltke, L.L.2    Greenblatt, D.J.3
  • 32
    • 18844410849 scopus 로고    scopus 로고
    • Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants
    • Bachmann KA, Lewis JD Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother. 2005 ; 39: 1064-1072.
    • (2005) Ann Pharmacother. , vol.39 , pp. 1064-1072
    • Bachmann, K.A.1    Lewis, J.D.2
  • 33
    • 33644861762 scopus 로고    scopus 로고
    • Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug-drug interactions: Pitfalls, progress and promise
    • Bachmann KA Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug-drug interactions: pitfalls, progress and promise. Curr Drug Metab. 2006 ; 7: 1-14.
    • (2006) Curr Drug Metab , vol.7 , pp. 1-14
    • Bachmann, K.A.1
  • 34
    • 33644922913 scopus 로고    scopus 로고
    • Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: Utilization of a microtiter plate assay and a dispersion model
    • Yamamoto T., Suzuki A., Kohno Y., Nagata K., Yamazoe Y. Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. Curr Drug Metab. 2006 ; 7: 135-146.
    • (2006) Curr Drug Metab , vol.7 , pp. 135-146
    • Yamamoto, T.1    Suzuki, A.2    Kohno, Y.3    Nagata, K.4    Yamazoe, Y.5
  • 35
    • 27444445468 scopus 로고    scopus 로고
    • Prediction of in vivo drug-drug interactions from in vitro data: Impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant
    • Brown HS, Ito K., Galetin A., Houston JB Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol. 2004 ; 60: 508-518.
    • (2004) Br J Clin Pharmacol. , vol.60 , pp. 508-518
    • Brown, H.S.1    Ito, K.2    Galetin, A.3    Houston, J.B.4
  • 36
    • 33645961595 scopus 로고    scopus 로고
    • The impact of in vitro binding on in vitro-in vivo extrapolations, projection of metabolic clearance and clinical drug-drug interactions
    • Grime K., Riley RJ The impact of in vitro binding on in vitro-in vivo extrapolations, projection of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab. 2006 ; 7: 251-264.
    • (2006) Curr Drug Metab , vol.7 , pp. 251-264
    • Grime, K.1    Riley, R.J.2
  • 37
    • 0036891924 scopus 로고    scopus 로고
    • Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors
    • Tran TH, von Moltke L., Venkatakrishnan K., Granda BW, Gibbs MA, Obach RS Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos. 2002 ; 30: 1441-1445.
    • (2002) Drug Metab Dispos. , vol.30 , pp. 1441-1445
    • Th, T.1    Von Moltke, L.2    Venkatakrishnan, K.3    Granda, B.W.4    Ma, G.5    Obach, R.S.6
  • 38
    • 0031466149 scopus 로고    scopus 로고
    • Nonspecific binding to microsomes: Impact of scale-up of in vitro intrinsic clearance to hepatic clearance assessed through examination of warfarin, imipramine, and propranolol
    • Obach RS Nonspecific binding to microsomes: impact of scale-up of in vitro intrinsic clearance to hepatic clearance assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos. 1997 ; 25: 1359-1369.
    • (1997) Drug Metab Dispos. , vol.25 , pp. 1359-1369
    • Obach, R.S.1
  • 39
    • 0032941364 scopus 로고    scopus 로고
    • Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver
    • Yamano K., Yamamoto K., Kotaki H., Sawada Y., Iga T. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Met Dispos. 1999 ; 27: 395-402.
    • (1999) Drug Met Dispos. , vol.27 , pp. 395-402
    • Yamano, K.1    Yamamoto, K.2    Kotaki, H.3    Sawada, Y.4    Iga, T.5
  • 40
    • 0032755435 scopus 로고    scopus 로고
    • Kotaki H, et al. Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome-P450 in rats
    • Yamano K., Yamamoto K., Kotaki H, et al. Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome-P450 in rats. Drug Met Dispos. 1999 ; 27: 1224-1231.
    • (1999) Drug Met Dispos. , vol.27 , pp. 1224-1231
    • Yamano, K.1    Yamamoto, K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.